IRIDEX CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.96 USD | +0.68% |
|
-1.99% | +5.34% |
| Mar. 26 | Transcript : IRIDEX Corporation, Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q4 Revenue $12.5M, vs. Street Est of $14.9M | MT |
Financials (USD)
| Sales 2024 * | 51.8M | Sales 2025 * | 53.9M | Capitalization | 48.11M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | -4M | EV / Sales 2024 * | 0.93 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.89 x |
| P/E ratio 2024 * |
-8
x | P/E ratio 2025 * |
-10.2
x | Employees | 111 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75% |
More Fundamentals
* Assessed data
More news
Latest transcript on IRIDEX Corporation
More recommendations
More press releases
| 1 day | +0.68% | ||
| 1 week | -1.99% | ||
| Current month | -0.67% | ||
| 1 month | +14.29% | ||
| 3 months | +10.86% | ||
| 6 months | +0.68% | ||
| Current year | +5.34% |
1 week
2.86
3.08
1 month
2.613.65
Current year
2.293.65
1 year
1.313.65
3 years
1.319.71
5 years
1.229.71
10 years
1.2216.64
| Managers | Title | Age | Since |
|---|---|---|---|
David I. Bruce
CEO | Chief Executive Officer | 64 | 18-04-12 |
Fuad Ahmad
DFI | Director of Finance/CFO | 54 | 20-11-10 |
Patrick Mercer
COO | Chief Operating Officer | 52 | 18-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beverly A. Huss
BRD | Director/Board Member | 64 | 22-03-16 |
Kenneth Ludlum
BRD | Director/Board Member | 70 | 19-04-01 |
Robert E. Grove
BRD | Director/Board Member | 75 | 18-10-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2.96 | +0.68% | 61,139 |
| 24-04-24 | 2.94 | -2.97% | 10,149 |
| 24-04-23 | 3.03 | +3.77% | 20,874 |
| 24-04-22 | 2.92 | +1.74% | 44,835 |
| 24-04-19 | 2.87 | -4.97% | 50,079 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.94
USD
Average target price
2
USD
Spread / Average Target
-31.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.34% | 47.78M | |
| +7.71% | 220B | |
| +6.25% | 185B | |
| +10.60% | 133B | |
| +26.73% | 107B | |
| -0.57% | 62.91B | |
| +15.42% | 53.34B | |
| -1.89% | 47.71B | |
| -1.91% | 40.29B | |
| +11.16% | 39.57B |
- Stock Market
- Equities
- IRIX Stock
